Research / Compound library

Look beyond
the compound name.

Compare the profile, follow the risk flags, and read the context behind each compound.

A map of the database,
not a list of recommendations.

Start with Foundation →

Explore by family

All compounds

Choose a family above, or search across the library.

79 matching profiles

›

Risk flags summarize the profile; they are not a validated safety score. Dose, duration, combinations, and evidence gaps matter.

§01.01

Anabolic AAS · ANDROGENIC

19 compounds

#	Compound	Route	Source reference	T½ · Decay	Risk flags	Profile
01	1-Testosterone DHB Related lesson →	INJ	Community: 300–400 mg/week total · Injection interval depends on ester; no fixed count in this claim · context required	~7d	▮▮▮▯▯ MEDIUM	Injectable DHT derivative Cutting Advanced only Lean gains Hardening
02	4-Androstenediol 4-AD	ORAL	PED-use amount not established here; Human androstenediol research exists; identity/formulation review pending	6h	▮▮▮▯▯ MEDIUM	Oral Aromatizer Beginner-friendly Hepatotoxic Mild
03	Anadrol Oxymetholone Related lesson →	ORAL	Community: 50–100 mg/day total · Source specifies a daily total, not how many administrations per day · source reference	8h	▮▮▮▯▯ MEDIUM	Oral DHT derivative Mass builder Advanced only Hepatotoxic Estrogenic effects Polycythemic C17-AA
04	Anavar Oxandrolone	ORAL	Community: 30–50 mg/day total · Source specifies a daily total, not how many administrations per day · source reference	8h	▮▮▯▯▯ MILD	Oral DHT derivative Cutting Beginner-friendly Mild Lipo-toxic
05	Dianabol Metandienone Related lesson →	ORAL	Community: 30–50 mg/day total · Source specifies a daily total, not how many administrations per day · source reference	6h	▮▮▮▯▯ MEDIUM	Oral Aromatizer Mass builder Hepatotoxic Water retention C17-AA
06	Epistane Methylepitiostanol	ORAL	PED-use amount not established here; Source identity conflict; primary adverse-event evidence available	6h	▮▮▮▯▯ MEDIUM	Oral DHT derivative Cutting Beginner-friendly Hepatotoxic Anti-estrogen
07	Equipoise Boldenone	INJ	Community: 400–600 mg/week total · Weekly total; administration frequency is a separate discussion · context required	~2.0wk	▮▮▮▯▯ MEDIUM	Injectable Aromatizer Mass builder Beginner-friendly Anti-estrogen Long ester Appetite Polycythemic Lab-interference
08	Halotestin Halo Related lesson →	ORAL	Community: 20–50 mg/day total · Daily total; source separately describes divided daily amounts · context required	6h	▮▮▮▮▯ HIGH	Oral DHT derivative Cutting Advanced only Hepatotoxic Neurotoxic C17-AA Ultra-hepatotoxic
09	Masteron Drostanolone	INJ	Community: 300–500 mg/week total · Source also gives daily/EOD administrations with a separate range · context required	~2d	▮▮▯▯▯ MILD	Injectable DHT derivative Cutting Anti-estrogen Hardening
10	Mibolerone Cheque Drops Related lesson →	ORAL	PED-use amount not established here; Community source exists; veterinary/preclinical lineage; no universal value	4h	▮▮▮▮▮ EXTREME	Oral DHT derivative Advanced only Extreme potency Neurotoxic C17-AA Ultra-hepatotoxic Hair unsafe
11	M-Tren Methyltrienolone Related lesson →	ORAL	PED-use amount not established here; Source exists; toxicity evidence; no universal value	6h	▮▮▮▮▮ EXTREME	Oral Cutting Advanced only Progestin Strong prolactin Extreme potency HPTA-killer C17-AA Ultra-hepatotoxic Nephrotoxic
12	Nandrolone Deca Related lesson →	INJ	Community: 400 mg/basis unspecified in source · Time denominator absent in the amount sentence; frequency discussion is separate · context required	~3d	▮▮▮▯▯ MEDIUM	Injectable Aromatizer 19-nor Mass builder Beginner-friendly Progestin Joint health Strong prolactin
13	Primo Primobolan	INJ	Community: 80–150 mg/day total · Source says at least once daily but does not define a fixed count · context required	~7d	▮▮▯▯▯ MILD	Injectable DHT derivative Cutting Beginner-friendly Mild Expensive Lean gains
14	Superdrol Methasterone Related lesson →	ORAL	Community: 10–30 mg/day total · Daily total; opening Average Dose section · context required	8h	▮▮▮▮▮ EXTREME	Oral DHT derivative Advanced only Hepatotoxic Extreme potency Ultra-hepatotoxic
15	Testosterone Test Related lesson →	INJ	Community: 500 mg/week total · Source lists E3D OR E3.5D alongside this weekly total · context required	~7d	▮▮▮▯▯ MEDIUM	Injectable Aromatizer Mass builder Beginner-friendly Test base
16	Trenbolone Tren Related lesson →	INJ	Community: 50 mg/day total · Daily total; acetate-specific community claim · context required	~1d	▮▮▮▮▯ HIGH	Injectable 19-nor Cutting Advanced only Progestin Strong prolactin Neurotoxic Nephrotoxic
17	Trestolone MENT Related lesson →	INJ	PED-use amount not established here; Community reference exists; experimental; implant research not injectable-dose support	~1d	▮▮▮▮▮ EXTREME	Injectable 19-nor Advanced only Progestin Extreme aromatizer Strong prolactin Extreme potency
18	Turinabol Tbol	ORAL	Community: 40–50 mg/day total · Source specifies a daily total, not how many administrations per day · source reference	16h	▮▮▮▯▯ MEDIUM	Oral Beginner-friendly Hepatotoxic Mild Lean gains C17-AA
19	Winstrol Stanozolol	ORAL	Community: 25–100 mg/day total · Daily amount; oral splitting and injectable cadence discussed separately · context required	8h	▮▮▮▯▯ MEDIUM	Oral DHT derivative Cutting Hepatotoxic Joint stress Hardening Lipo-toxic Collagen-inhibitor C17-AA

§01.02

Peptide GHRH · GHRP · Healing · Growth

25 compounds

#	Compound	Route	Source reference	T½ · Decay	Risk flags	Profile
01	BPC-157 Body Protection Compound Related lesson →	INJ	PED-use amount not established here; FDA describes limited human safety information and immunogenicity concerns.	4h	▮▮▯▯▯ MILD	Injectable Peptide Recovery
02	CJC-1295 CJC-1295 DAC Related lesson →	INJ	PED-use amount not established here; Two short controlled trials measured endocrine responses, not a universal treatment program.	~7d	▮▮▯▯▯ MILD	Injectable Peptide Growth hormone Recovery
03	FOXO4-DRI FOXO4 D-retro-inverso peptide	INJ	PED-use amount not established here; Aging-mouse and endothelial-cell experiments investigated a proposed senolytic mechanism.	12h	▮▮▯▯▯ MILD	Injectable Peptide
04	GHRP-2 Growth Hormone Releasing Peptide-2 Related lesson →	INJ	PED-use amount not established here; FDA reports serious events with unestablished causality and peptide-quality concerns.	0.5h	▮▮▯▯▯ MILD	Injectable Peptide Growth hormone Recovery
05	GHRP-6 Growth Hormone Releasing Peptide-6	INJ	PED-use amount not established here; FDA cites limited safety data and concerns involving cortisol and glucose.	0.5h	▮▮▯▯▯ MILD	Injectable Peptide Growth hormone Recovery
06	Hexarelin Examorelin	INJ	PED-use amount not established here; Small acute experiment measured growth-hormone response.	0.5h	▮▮▯▯▯ MILD	Injectable Peptide Growth hormone Recovery
07	hGH Human Growth Hormone Related lesson →	INJ	PED-use amount not established here; Somatropin labeling distinguishes diagnoses, age groups and individualized response monitoring.	4h	▮▮▯▯▯ MILD	Injectable Cutting Growth hormone Recovery Fat loss
08	HGH Fragment 176-191 HGH Frag	INJ	Reference review incomplete for this profile	0.5h	▮▮▯▯▯ MILD	Injectable Cutting Peptide Fat loss
09	Humalog Insulin Insulin Lispro Related lesson →	INJ	PED-use amount not established here; The label requires individualized treatment based on metabolic needs, glucose results and glycemic goals.	1.0h	▮▮▮▮▯ HIGH	Injectable Advanced only
10	Humulin R Regular Human Insulin Related lesson →	INJ	PED-use amount not established here; The label requires individualized treatment based on metabolic needs, glucose results and glycemic goals.	4h	▮▮▮▮▯ HIGH	Injectable Advanced only
11	IGF-1 DES Des(1-3)IGF-1	INJ	Reference review incomplete for this profile	0.2h	▮▮▯▯▯ MILD	Injectable Recovery
12	IGF-1 LR3 Long-R3 IGF-1 Related lesson →	INJ	Reference review incomplete for this profile	20h	▮▮▯▯▯ MILD	Injectable Cutting Recovery
13	Ipamorelin IPA Related lesson →	INJ	PED-use amount not established here; FDA notes serious events in intravenous research and insufficient safety data for other injectable routes.	2h	▮▮▯▯▯ MILD	Injectable Mild No water retention Peptide Growth hormone Recovery
14	Lantus Insulin Insulin Glargine Related lesson →	INJ	PED-use amount not established here; The label requires individualized treatment based on metabolic needs, glucose results and glycemic goals.	~1d	▮▮▮▮▯ HIGH	Injectable Advanced only
15	Melanotan II MT-II	INJ	PED-use amount not established here; FDA lists serious reported adverse events; causation and frequency are not established.	~1d	▮▮▯▯▯ MILD	Injectable Cutting Peptide
16	MGF Mechano Growth Factor	INJ	PED-use amount not established here; The FDA entry concerns PEG-MGF, not every substance called MGF.	~3d	▮▮▯▯▯ MILD	Injectable Recovery
17	MOTS-c Mitochondrial ORF of the 12S rRNA type-c	INJ	PED-use amount not established here; FDA reports no identified human exposure data and insufficient safety information.	4h	▮▮▯▯▯ MILD	Injectable Peptide
18	Novolog Insulin Insulin Aspart Related lesson →	INJ	PED-use amount not established here; The label requires individualized treatment based on metabolic needs, glucose results and glycemic goals.	1.0h	▮▮▮▮▯ HIGH	Injectable Advanced only
19	PE-22-28 Spadin analogue	INJ	PED-use amount not established here; Cell experiments and mouse behavioral studies provide preclinical context.	2h	▮▮▯▯▯ MILD	Injectable Peptide
20	PT-141 Bremelanotide	INJ	PED-use amount not established here; scoped source context available	2h	▮▮▯▯▯ MILD	Injectable Libido Peptide
21	Retatrutide GLP-1/GIP/glucagon triple agonist Related lesson →	INJ	PED-use amount not established here; Historical phase 2 trial has population-specific exposure context; current FDA page still describes it as unapproved.	~7d	▮▮▯▯▯ MILD	Injectable Cutting Peptide
22	Semaglutide Ozempic Related lesson →	INJ	PED-use amount not established here; scoped source context available	~7d	▮▮▯▯▯ MILD	Injectable Cutting Peptide
23	TB-500 Thymosin Beta-4 Related lesson →	INJ	PED-use amount not established here; FDA reports no identified human exposure data for the specified fragment.	~7d	▮▮▯▯▯ MILD	Injectable Peptide Recovery
24	Tesamorelin Egrifta	INJ	PED-use amount not established here; Label-backed reference must retain the exact product and medical indication.	0.5h	▮▮▯▯▯ MILD	Injectable Peptide Growth hormone Fat loss
25	Tirzepatide Mounjaro Related lesson →	INJ	PED-use amount not established here; scoped source context available	~5d	▮▮▯▯▯ MILD	Injectable Cutting Peptide

§01.03

SARMs Selective Androgen Receptor Modulators

8 compounds

#	Compound	Route	Source reference	T½ · Decay	Risk flags	Profile
01	ACP-105 ACP-105	ORAL	Reference review incomplete for this profile	8h	▮▮▯▯▯ MILD Human risk uncertain	Oral Mild
02	Andarine S-4	ORAL	PED-use amount not established here; FDA warning letter names S-4 Andarine among marketed unapproved products.	4h	▮▮▮▯▯ MEDIUM Human risk uncertain	Oral Cutting
03	LGD-3303 LGD-3303	ORAL	Reference review incomplete for this profile	6h	▮▮▮▯▯ MEDIUM Human risk uncertain	Oral
04	LGD-4033 Ligandrol	ORAL	PED-use amount not established here; Short controlled human trial examined safety, pharmacokinetics and exploratory physical outcomes.	~1d	▮▮▮▯▯ MEDIUM Human risk uncertain	Oral Beginner-friendly Hepatotoxic Mild Lean gains
05	Ostarine MK-2866	ORAL	PED-use amount not established here; Controlled phase 2 study provides context for enobosarm exposure in older adults.	~1d	▮▮▯▯▯ MILD Human risk uncertain	Oral Beginner-friendly Mild Lean gains
06	RAD-140 Testolone	ORAL	PED-use amount not established here; Official record verifies a first-in-human oncology trial.	16h	▮▮▮▯▯ MEDIUM Human risk uncertain	Oral
07	S-23 S-23 Related lesson →	ORAL	PED-use amount not established here; Reviewed primary study concerns male contraception in rats.	12h	▮▮▮▯▯ MEDIUM Human risk uncertain	Oral
08	YK-11 YK11 Related lesson →	ORAL	PED-use amount not established here; Cell study reports follistatin expression and myogenic differentiation.	6h	▮▮▮▯▯ MEDIUM Human risk uncertain	Oral

§01.04

Metabolic PPARδ · GLP-1 · Rev-Erb · Metabolic Modulators

5 compounds

#	Compound	Route	Source reference	T½ · Decay	Risk flags	Profile
01	Cardarine GW501516	ORAL	PED-use amount not established here; GW501516 was investigated for lipid endpoints in two related clinical studies.	16h	▮▮▮▯▯ MEDIUM Animal cancer signal	Oral Cutting Non-suppressive Fat loss
02	Clenbuterol Clen	ORAL	PED-use amount not established here; Community source exists; documented harm; no universal value	~1d	▮▯▯▯▯ LOW	Oral Cutting Non-suppressive Fat loss Stimulant Beta-agonist
03	MK-677 Ibutamoren Related lesson →	ORAL	PED-use amount not established here; Older-adult trial measured body composition; increased fat-free mass did not improve strength or function.	~1d	▮▯▯▯▯ LOW	Oral Non-suppressive
04	SR9009 Stenabolic	ORAL	PED-use amount not established here; Mouse/cell studies support experimental context and also question exclusive REV-ERB specificity.	4h	▮▯▯▯▯ LOW	Injectable Oral Cutting Non-suppressive Fat loss
05	Yohimbine Yohimbine HCl	ORAL	PED-use amount not established here; Formulation-specific evidence review needed	1.0h	▮▯▯▯▯ LOW	Oral Cutting Fat loss Stimulant Alpha-2 antagonist

§01.05

Ancillary AI · SERM · PCT · Support

22 compounds

#	Compound	Route	Source reference	T½ · Decay	Risk flags	Profile
01	Arimidex Anastrozole	ORAL	Community: 0.5 mg/administration · Every 3 days OR every 3.5 days · context required	~2d	▮▯▯▯▯ LOW	Oral Ancillary AI
02	Aromasin Exemestane	ORAL	Community: 12.5 mg/administration · Every 3 days OR every 3.5 days · context required	~1d	▮▯▯▯▯ LOW	Oral Ancillary AI
03	Ashwagandha Withania somnifera	ORAL	PED-use amount not established here; Product-specific studied references may be shown after extract matching	12h	▮▯▯▯▯ LOW	Oral Ancillary
04	Astragalus Astragalus membranaceus	ORAL	PED-use amount not established here; Condition/formulation-specific evidence; no universal value	12h	▮▯▯▯▯ LOW	Oral Ancillary
05	Cabergoline Caber	INJ	PED-use amount not established here; scoped source context available	~7d	▮▯▯▯▯ LOW	Ancillary
06	Citrus Bergamot Bergamot Extract	ORAL	PED-use amount not established here; Product-specific trial exposure available	12h	▮▯▯▯▯ LOW	Oral Ancillary
07	Clomid Androxal	ORAL	PED-use amount not established here; Source references available; context required	~5d	▮▮▯▯▯ MILD	Oral Ancillary SERM PCT
08	Clomiphene Clomid	ORAL	PED-use amount not established here; Source references available; context required	~5d	▮▯▯▯▯ LOW	Oral Ancillary
09	Dutasteride Avodart	ORAL	PED-use amount not established here; Source references available; context required	~7.1wk	▮▯▯▯▯ LOW	Oral Ancillary
10	Finasteride Propecia	ORAL	PED-use amount not established here; scoped source context available	~1d	▮▯▯▯▯ LOW	Oral Ancillary
11	Glucosamine Glucosamine Sulfate	ORAL	PED-use amount not established here; Osteoarthritis research exists; salt/formulation and context required	~1d	▮▯▯▯▯ LOW	Oral Ancillary
12	Glycine Glycine supplement	ORAL	PED-use amount not established here; Studied oral bedtime exposure available; small-study context	4h	▮▯▯▯▯ LOW	Oral Ancillary
13	HCG Human Chorionic Gonadotropin	INJ	Community: 250 IU/administration · Every other day · context required	~1d	▮▯▯▯▯ LOW	Injectable Ancillary
14	HMG Human Menopausal Gonadotropin	INJ	PED-use amount not established here; Source references available; context required	~1d	▮▯▯▯▯ LOW	Injectable Ancillary
15	ITPP Myo-Inositol Trispyrophosphate	INJ	PED-use amount not established here; Early-phase oncology exposure exists; no universal value	12h	▮▯▯▯▯ LOW	Injectable
16	Letrozole Femara	ORAL	PED-use amount not established here; Source references available; context required	~2d	▮▯▯▯▯ LOW	Oral Ancillary AI
17	Mesterolone Proviron	ORAL	Community: 25–100 mg/day total · Daily total; source discusses splitting as optional · context required	12h	▮▯▯▯▯ LOW	Oral DHT derivative Anti-estrogen Libido Ancillary SHBG-suppressive
18	NAD+ Nicotinamide Adenine Dinucleotide	ORAL	PED-use amount not established here; Pilot infusion evidence exists; wellness efficacy and other routes unresolved	0.5h	▮▯▯▯▯ LOW	Injectable Oral Recovery
19	Omega-3 EPA/DHA Fish Oil	ORAL	PED-use amount not established here; EPA/DHA-specific dietary or clinical reference; not fish-oil mass	~1d	▮▯▯▯▯ LOW	Oral Ancillary
20	Tamoxifen Nolvadex	ORAL	PED-use amount not established here; Source references available; context required	~7d	▮▯▯▯▯ LOW	Oral Ancillary
21	TUDCA Tauroursodeoxycholic Acid	ORAL	PED-use amount not established here; Source references available; context required	~1d	▮▯▯▯▯ LOW	Oral Ancillary
22	UDCA Ursodeoxycholic Acid	ORAL	PED-use amount not established here; Source references available; context required	~1d	▮▯▯▯▯ LOW	Oral Ancillary